Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic ...

Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.

PC: What risks do you foresee for companies developing first-in-class therapies if patient perspectives are no longer formally incorporated into regulatory discussions? Leuchter: Eliminating patient ...

The Complexities of Drug Discounting A Pharmaceutical Executive article explores how the growing complexity and lack of transparency in drug discount programs are undermining their intended benefits, ...

Exploring Perspectives of Fair Market Value in Clinical Trial Budgeting An Applied Clinical Trials article explores the complex and often conflicting perspectives of sponsors, CROs, and research sites ...

Key Takeaways Speed is Critical. The first 24 hours after a prescription are crucial—nearly half of patients are lost immediately without efficient onboarding. Rapid, streamlined hub services are ...

Key Takeaways UCB is investing $5 billion in a new US biologics manufacturing facility, aiming to boost its production capabilities, create 800 jobs, and strengthen its global supply chain. The ...